Veloxis Pharmaceuticals
Closed portfolio with an early-phase archive tilt
According to ClinicalTrials.gov-derived indexes, Veloxis Pharmaceuticals sits in the top decile of US sponsors by registered trial count (#934 of 15,742 sponsors by registered trial count).
Veloxis Pharmaceuticals: 15 sponsored US clinical trials, none currently recruiting.
Veloxis Pharmaceuticals sponsors 15 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 13 completed. 5 of these trials are in Phase 3-4 (later-stage) and 10 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Renal Failure, with 2 trials.
Top-decile sponsor footprint
Veloxis Pharmaceuticals ranks in the top decile of sponsors by registered trial count (#934 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
13 of 15 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (86.7%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Indexed trials (enrollment closed)
15 total, page 1 of 1
A Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VEL-101
NCT05238493
Assess Safety and Tolerability of ART-123 + FOLFOX + Bevacizumab in Metastatic Colorectal Cancer Patients
NCT05251727
Pharmacokinetic Comparison Of All FK-506 Formulations
NCT02339246
Crossover Study to Compare PK of Once Daily LCP-Tacro Tablets to Generic Tacrolimus Capsules Twice Daily.
NCT01962922
Multicenter, Prospective, Rand, PK Study of LCP-Tacro™ Compared to Prograf® Capsules in De Novo Adult Kidney Transplant
NCT01666951
Switching Study of Kidney Transplant Patients With Tremor to LCP-Tacro (STRATO)
NCT01438710
Double-Blind,Double-Dummy,Efficacy/Safety,LCP-Tacro™ Vs Prograf®,Prevention Rejection,De Novo Adult Kidney Tx
NCT01187953
Safety and Efficacy of LCP-Tacro™ Once Daily in Stable Renal Transplant Patients Converted From Prograf® Twice Daily
NCT00817206
Pharmacokinetics of LCP-Tacro™ Once Daily and Prograf® Twice A Day in Adult De Novo Liver Transplant Patients
NCT00772148
Pharmacokinetics of LCP-Tacro(TM) Once Daily And Prograf® Twice A Day in Adult De Novo Kidney Transplant Patients
NCT00765661
LCP-Tacro vs. Azathioprine for the Treatment of Autoimmune Hepatitis
NCT00608894
Pharmacokinetics of LCP-Tacro in Stable Liver Transplant Patients
NCT00608244
12-Month, Open-Label, Extension Study of LCP-AtorFen in Dyslipidemia
NCT00664859
Study of Atorvastatin/Fenofibrate (LCP-AtorFen) Combination Therapy in Dyslipidemia
NCT00504829
Pharmacokinetics of LCP-Tacro in Stable Kidney Transplant Patients
NCT00496483
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 2 |
| Phase 2 | 8 |
| Phase 3 | 5 |
Therapeutic Areas
How the Veloxis Pharmaceuticals early-phase archive is shaped
15 indexed studies, none listed as recruiting (0% open); 13 completed (87%).
Phase mix: 5 late (III/IV) vs 10 early (I/II) (early-phase heavy).
Top condition: Renal Failure (2 trials), 1 other listed.
How to read a closed sponsor archive
When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.
Veloxis Pharmaceuticals: archived-pipeline peers nationwide
Peers matched on 15 indexed studies with no current recruiting: volume and archive shape, not condition overlap.
Veloxis Pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 15 archived trials
- Allakos · 15 trials · 0% recruiting
- Arbor Research Collaborative for Health · 15 trials · 33% recruiting
- Arena Pharmaceuticals · 15 trials · 0% recruiting
- Arrowhead Pharmaceuticals · 15 trials · 20% recruiting
Sponsors with similar archive density (± trial count)
- 10xBio · 0% recruiting · 3 trials
- 22nd Century Group · 0% recruiting · 3 trials
- 23andMe · 0% recruiting · 6 trials
- 3-C Institute for Social Development · 0% recruiting · 14 trials
Related
What to do with this Veloxis Pharmaceuticals page
15 registered trials is a research-attention snapshot, not an endorsement of Veloxis Pharmaceuticals or any single study.
- None of Veloxis Pharmaceuticals's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Renal Failure is the condition Veloxis Pharmaceuticals studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Renal Failure trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Veloxis Pharmaceuticals pipeline card: 15 registered trials from official public datasets.Report a data error.